The purpose of this study is to determine whether photopheresis therapy can be used to
improve the clinical course of early stage cutaneous T-cell lymphoma (CTCL). Currently,
photopheresis is performed as a palliative treatment for late stage CTCL. However, recent
studies have demonstrated that patients with early stage CTCL may have markers in their blood
which were previously observed primarily in late stage disease, such as clonal T cell
populations. Considering these findings, the study aims to investigate whether photopheresis
therapy may be used earlier in the disease course to produce a clinical response.